Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497729 | 0.88 | POLB (0.62) | SMN1; SMN2POLBLMNATDP1KDM4E | |
| SCHEMBL22962259 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2POLBLMNATDP1KDM4E | |
| SCHEMBL230840 | 0.81 | POLB (0.58) | SMN1; SMN2POLBLMNATDP1KDM4E | |
| SCHEMBL11268441 | 0.80 | POLB (0.65) | SMN1; SMN2POLBLMNATDP1KDM4E | |
| SCHEMBL18250317 | 0.76 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNATDP1TP53MAPT | |
| SCHEMBL229041 | 0.75 | POLB (0.67) | SMN1; SMN2POLBLMNATDP1KDM4E | |
| SCHEMBL29668561 | 0.75 | KCNH2 (0.51) | SMN1; SMN2LMNAKDM4ETP53MEN1 | |
| SCHEMBL29668739 | 0.75 | KCNH2 (0.51) | SMN1; SMN2LMNAKDM4ETP53MEN1 | |
| SCHEMBL10368381 | 0.75 | POLB (0.54) | SMN1; SMN2POLBLMNATDP1KDM4E | |
| SCHEMBL3059715 | 0.74 | MEN1 (0.64) | SMN1; SMN2POLBLMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082425-A1 | For therapy of obesity and diabetes | NEUROGEN CORPORATION | 2002-06-27 | — | — | US | disclosed |
| EP-1165519-A1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIDIABETICS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6271241-B1 | BENZYLIMIDAZOLE DERIVATIVES AS MODULATORS OF BLOOD GLUCOSE LEVELS, ALSO USEFUL AS PROBES FOR LOCALIZATION OF CELLULAR RECEPTORS INVOLVED WITH SUCH MODULATION; FOOD METABOLISM AND FEEDING; TREATING DIABETES, OBESITY | NEUROGEN CORPORATION | 2001-08-07 | — | — | US | disclosed |
| WO-2000059887-A1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIDIABETICS | NEUROGEN CORPORATION (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082425-A1 | For therapy of obesity and diabetes | GPR119, GLP1R, NPY1R | SMN1; SMN2 4403/4885POLB 4177/4885LMNA 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.